Greenwich LifeSciences, Inc.

GLSI Stock Report Card

Today's performance

C

Performance

Score: 100/100

A+

GLSI returned 35.23% in the last 12 months. Based on the other stocks in its sector with an average return of -5.69%, its performance is above average giving it a grade of 100 of 100.

Sentiment

Score: 68/100

GLSI had a bullish sentiment score of 68.39% across Twitter and StockTwits over the last 12 months. It had an average of 16.54 posts, 10.27 comments, and 38.70 likes per day.

Technicals

Score: 11/100

GLSI receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

Score: 53/100

GLSI has missed earnings 2 times in the last 20 quarters.

Profit

Score: 10/100

Out of the last 16 quarters, GLSI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score: 42/100

GLSI has had a lower than average amount of volatility over the last 12 months giving it a grade of 41 of 100.

Greenwich LifeSciences, Inc. Summary

Nasdaq / GLSI

Healthcare

Biotechnology

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Power up your portfolio

Build a portfolio of the best stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

GLSI scored poorly on our reportcard. Here are some similar companies and how they performed.

Novo-Nordisk A/S

$NVO Stock Report Card

AstraZeneca PLC

$AZN Stock Report Card

Atara Biotherapeutics, Inc

$ATRA Stock Report Card

Tabula Rasa HealthCare, Inc. Common Stock

$TRHC Stock Report Card

Protalix BioTherapeutics, Inc. Common Stock

$PLX Stock Report Card

Corvus Pharmaceuticals, Inc.

$CRVS Stock Report Card

ProPhase Labs, Inc. Common Stock (DE)

$PRPH Stock Report Card

INmune Bio Inc. Common stock

$INMB Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.